Prednisolone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Prednisolone: From Systemic Corticosteroid Therapy to Alopecia Areata
One-Sentence Summary
Prednisolone is a synthetic glucocorticoid corticosteroid, long used systemically for a broad range of inflammatory and autoimmune conditions. The TxGNN model predicts it may be effective for Alopecia Areata, with 18 clinical trials and 20 publications identified in the evidence base — though only a small subset directly involves prednisolone/corticosteroid therapy for this specific condition.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (no ARTG licence on file). Prednisolone is generically known as a synthetic corticosteroid used broadly for anti-inflammatory and immunosuppressive therapy |
| Predicted New Indication | Alopecia areata |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L3 |
| Australia Market Status | Not currently marketed in Australia |
| Number of ARTG Entries | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, prednisolone is a synthetic glucocorticoid that suppresses T-cell activation, cytokine release, and inflammatory cascades — the basis for its long-standing systemic use across many inflammatory and autoimmune diseases.
Alopecia areata is a T-cell-mediated (particularly CD8+NKG2D+) autoimmune disease in which the immune-privileged niche of the hair follicle is attacked. Glucocorticoids inhibit T-cell activation and pro-inflammatory cytokine release, and this mechanism is already supported by clinical practice: systemic and pulse-dose prednisolone/methylprednisolone are established (if off-label) options for moderate-to-severe alopecia areata. This means the TxGNN prediction largely reflects existing clinical use rather than a wholly novel hypothesis.
Clinical Trial Evidence
Of the 18 trials returned for this query, most concern systemic lupus erythematosus or unrelated conditions and are not directly relevant to prednisolone use in alopecia areata. The trials with direct relevance are:
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT01167946 | Phase 4 | Completed | 42 | Oral mega-pulse methylprednisolone (higher dose, more frequent pulsing) trialled in patients with severe, treatment-resistant alopecia areata (totalis/universalis/ophiasic types) who had failed standard pulse-steroid dosing |
| NCT07101471 | N/A | Completed | 296 | Observational safety/effectiveness study of tofacitinib in alopecia; participants received tofacitinib with or without adjuvant prednisolone, no comparator arm |
| NCT01017510 | N/A | Unknown | 20 | Compared needle-free (DERMOJET) versus conventional syringe delivery of intralesional corticosteroid for alopecia areata; no prior published comparison of the two delivery methods existed |
The remaining 15 trials in the evidence set (mostly Phase 2/3 SLE studies of non-prednisolone agents such as baricitinib, sirolimus, and various monoclonal antibodies) were assessed as low relevance and are not shown.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37870096 | 2023 | Review (Cochrane network meta-analysis) | Cochrane Database of Systematic Reviews | Network meta-analysis comparing immunosuppressants (including corticosteroids), hair growth stimulants and contact immunotherapy for alopecia areata |
| 30191561 | 2019 | Systematic review | Australasian Journal of Dermatology | Systematic review (1946–2018) of systemic treatments for alopecia areata, totalis and universalis; evaluates RCT evidence quality across agents |
| 37992355 | 2023 | Review | Dermatology Practical & Conceptual | Reviews efficacy, relapse rates, adverse effects and prognostic factors for corticosteroid pulse therapy in alopecia areata |
| 15692475 | 2005 | Placebo-controlled trial | Journal of the American Academy of Dermatology | First placebo-controlled evaluation of oral pulse prednisolone therapy in alopecia areata; noted no prior randomised/placebo-controlled data existed |
| 21572877 | 2009 | Cohort | Dermato-Endocrinology | Medium-dose prednisolone pulse therapy effective in early-stage alopecia areata, though significant side effects can lead to treatment discontinuation |
| 35986630 | 2022 | Cohort (retrospective) | Dermatologic Therapy | Retrospective comparison of methylprednisolone alone versus combined with methotrexate in 26 patients with extensive alopecia areata |
| 41243342 | 2025 | Review | Journal of Dermatological Treatment | Case-based review of dexamethasone oral mini-pulse achieving durable remission in severe alopecia areata when JAK inhibitors are unavailable or unsuitable |
| 22426909 | 2012 | Cohort | Saudi Medical Journal | Intensive oral mega-pulse methylprednisolone regimen evaluated for efficacy and safety in severe, therapy-resistant alopecia areata |
| 28140540 | 2017 | Cohort | Journal der Deutschen Dermatologischen Gesellschaft | Sequential high- then low-dose systemic corticosteroid therapy in severe childhood alopecia areata; rapid response but relapse common after discontinuation |
| 26179196 | 2015 | Cohort (long-term follow-up) | Dermatologic Therapy | Combined oral pulse and topical corticosteroid therapy in 65 children/adolescents with severe alopecia areata (>30% scalp); median 96-month follow-up |
Australia Market Information
Prednisolone currently has no ARTG entries on file in this evidence pack (market_status: 未上市 / not marketed, total_licenses: 0). No product name, dosage form or approved indication text is available to populate a licence table.
Safety Considerations
No safety data (key warnings, contraindications or drug interactions) is available in this evidence pack, and the drug is not currently registered in Australia, so no TGA-approved Product Information exists to reference. Safety review should be based on overseas corticosteroid Product Information (e.g. other jurisdictions’ prednisolone PI) pending TGA registration data.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Systemic/pulse corticosteroid use (including prednisolone and methylprednisolone) in moderate-to-severe alopecia areata is supported by a Cochrane network meta-analysis, systematic reviews, a placebo-controlled trial and multiple cohort studies — this is largely established off-label clinical practice rather than a purely novel TxGNN hypothesis. However, the drug is not currently registered or marketed in Australia, and safety/MOA data are unavailable.
To proceed, the following is needed:
- TFDA/TGA-equivalent Product Information (warnings, contraindications, drug interactions) — currently flagged as a Blocking data gap (DG001)
- Detailed mechanism-of-action documentation from DrugBank — flagged as a High-severity data gap (DG002)
- Assessment of the ARTG registration pathway, since prednisolone currently has zero Australian licences on file
- Dermatology specialist input on risk–benefit of chronic/pulse corticosteroid therapy for this non-life-threatening dermatologic condition, given the modest evidence base once SLE and unrelated trials are excluded
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.